{"created":"2023-07-27T06:38:36.743953+00:00","id":26738,"links":{},"metadata":{"_buckets":{"deposit":"c5f70afc-da9d-476c-bbe8-b1d364abed6e"},"_deposit":{"created_by":3,"id":"26738","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"26738"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00026738","sets":["1761:1762:1763"]},"author_link":["45099","45101","45100","22059","27534","45098","471"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2001-08-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"398","bibliographicPageStart":"392","bibliographicVolumeNumber":"27","bibliographic_titles":[{"bibliographic_title":"医療薬学 = Japanese Journal of Pharmaceutical Health Care and Sciences"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The control of drug use for Parkinson's disease is very important for both the QOL and ADL of patients. Nowadays, patients with Parkinson's disease are treated with the concomitant use with L-dopa, dopamine receptor agonists and norepinephrine receptor agonists. However, these drugs elicit some adverse effects. Therefore, we tried to search for the effects and adverse effects, based on patient histories. As a result of our investigations, most patients broke out with tremors and were administered anticholinergic drugs, while a few patients were treated with L-dopa as the first drug of choice. Avoid the administration of L-dopa at first seemed to help prevent the onset of Wearing-off or On-off phenomenon. Gastric mucosal cytoprotective drugs appeared to be effective for preventing of gastric symptoms due to drugs for Parkinson's disease. Moreover, we found that mental symptoms only rarely occurred after the readministration of anticholinergic drugs. We must be careful to treat patients with brain infarction after the onset of mental symptoms. These results are valuable for helping to improve the treatment of Parkinson's disease, and may also help in performing further studies on the use of new drugs.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本医療薬学会 = Japanese Society of Pharmaceutical Health Care and Sciences"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.5649/jjphcs.27.392","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.jsphcs.jp/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/jjphcs/-char/ja/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://ci.nii.ac.jp/naid/110001166537/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © JSPHCS Japanese Society of Pharmaceutical Health Care and Sciences"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA11527197","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1346-342X","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大川, 浩子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"谷本, 明日香"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"旭, 満里子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"成橋, 和正"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"松下, 良"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"坂尻, 顕一"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"宮本, 謙一"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"HO-PR-MIYAMOTO-K-392.pdf","filesize":[{"value":"893.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"HO-PR-MIYAMOTO-K-392.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/26738/files/HO-PR-MIYAMOTO-K-392.pdf"},"version_id":"24a6c61b-f186-4f26-922c-319efe74807f"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"パーキンソン病患者のカルテ調査による薬剤の使用状況とADLに及ぼす影響","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"パーキンソン病患者のカルテ調査による薬剤の使用状況とADLに及ぼす影響"},{"subitem_title":"Study of Effect of Pharmacotherapy on ADL in Patients with Parkinson's Disease Based on Medical Report","subitem_title_language":"en"}]},"item_type_id":"4","owner":"3","path":["1763"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"26738","relation_version_is_last":true,"title":["パーキンソン病患者のカルテ調査による薬剤の使用状況とADLに及ぼす影響"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-27T21:19:51.698041+00:00"}